More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
US FDA Accepts NDA for Glaukos’ Epioxa for Epi-On Crosslinking Therapy
Author: Jennie Crabbe
Glaukos, of Aliso Viejo, California, reported Feb. 24 that the US FDA had accepted its new drug application for Epioxa, an epi-on version of the company’s iLink corneal crosslinking therapy, for the treatment of keratoconus. The FDA set a Prescription Drug User Fee Act (PDUFA) target action date of Oct. 20, 2025. Epioxa is designed to reduce the treatment’s procedure and recovery time and improve the comfort of the patient. Glaukos’ first-generation iLink procedure takes roughly an hour and r...
